Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice
Viruses · 2024
DOI: 10.3390/v16020211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Chenxing Lu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Develo…. Hauptthemen laut MEDLINE: Rotavirus, Rotavirus Vaccines, Rotavirus Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Science and Technology Special Project of Yunnan Province (Biomedicine), Science and Technology Project of Yunnan Province-general program, CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Rotaviruses (RVs) are a major cause of diarrhea in young children worldwide. The currently available and licensed vaccines contain live attenuated RVs. Optimization of live attenuated RV vaccines or developing non-replicating RV (e.g., mRNA) vaccines is crucial for reducing the morbidity and mortality from RV infections. Herein, a nucleoside-modified mRNA vaccine encapsulated in lipid nanoparticles (LNP) and encoding the VP7 protein from the G1 type of RV was developed. The 5′ untranslated region of an isolated human RV was utilized for the mRNA vaccine. After undergoing quality inspection, the VP7-mRNA vaccine was injected by subcutaneous or intramuscular routes into mice. Mice received three injections in 21 d intervals. IgG antibodies, neutralizing antibodies, cellular immunity, and gene expression from peripheral blood mononuclear cells were evaluated. Significant differences in levels of IgG antibodies were not observed in groups with adjuvant but were observed in groups without adjuvant. The vaccine without adjuvant induced the highest antibody titers after intramuscular injection. The vaccine elicited a potent antiviral immune response characterized by antiviral clusters of differentiation CD8+ T cells. VP7-mRNA induced interferon-γ secretion to mediate cellular immune responses. Chemokine-mediated signaling pathways and immune response were activated by VP7-mRNA vaccine injection. The mRNA LNP vaccine will require testing for protective efficacy, and it is an option for preventing rotavirus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Kunming 650118, China.
Förderung
- Major Science and Technology Special Project of Yunnan Province (Biomedicine)
- Science and Technology Project of Yunnan Province-general program
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- Yunnan Province Innovative Vaccine Technology and Industrial Transformation Platform
- Science and Technology Project of Yunnan Province—general program
Zitieren
APA
Lu, C., Li, Y., Chen, R., Hu, X., Leng, Q., Song, X., Lin, X., Ye, J., Wang, J., Li, J., Yao, L., Tang, X., Kuang, X., Zhang, G., Sun, M., Zhou, Y., & Li, H. (2024). Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice. Viruses. https://doi.org/10.3390/v16020211
Vancouver
Lu C, Li Y, Chen R, Hu X, Leng Q, Song X, et al. Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice. Viruses. 2024. doi:10.3390/v16020211
BibTeX
@article{Lu2024,
author = {Lu, Chenxing and Li, Yan and Chen, Rong and Hu, Xiaoqing and Leng, Qingmei and Song, Xiaopeng and Lin, Xiaochen and Ye, Jun and Wang, Jinlan and Li, Jinmei and Yao, Lida and Tang, Xianqiong and Kuang, Xiangjun and Zhang, Guangming and Sun, Maosheng and Zhou, Yan and Li, Hongjun},
title = {Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16020211}
}
EUVIMED